AMGN and BMY Related Headlines
Go Back- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- Barclays launches U.S. biopharma coverage with four preferred picks
- 14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
- Bernstein on IRA pricing: $245 really is the floor
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
